Jagsonpal indicates it is assessing acquisition options to deploy capital in EBITDA-accretive opportunities, prioritising value for shareholders while keeping cash outlays disciplined.
AI Assistant
Jagsonpal Pharmaceuticals Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.